Legend Biotech

Legend Biotech

Legend Biotech was founded as a clinical-stage biopharmaceutical company focused on cell therapies for cancer. The firm's wealth-creation event traces to its 2017 collaboration with Janssen, a Johnson & Johnson subsidiary, to co-develop ciltacabtagene autoleucel (Carvykti). Carvykti received FDA approval in February 2022 for relapsed or refractory multiple myeloma, generating $500 million in 2023 revenue and triggering milestone payments that turned Legend into a multi-billion-dollar entity. The firm's investment office, based in San Francisco, manages proceeds from these commercial milestones, focusing on biotechnology, cell engineering, and oncology-related startups. The investment strategy concentrates on direct equity stakes in early-stage biotech companies developing enabling technologies for cell therapy — including gene editing platforms, novel CAR constructs, and allogeneic cell manufacturing. Geographic focus spans the United States and China, reflecting Legend's dual operating base. The office participates in Series A and B rounds, occasionally co-investing alongside life-sciences venture firms. Confirmed direct investments include positions in biotechnology startups developing CRISPR delivery systems and next-generation cell-engineering tools (per public record). The firm does not openly disclose a fund structure and appears to deploy through direct balance-sheet investments rather than through commingled vehicles. Team composition is deliberately lean; the office operates with a small group of investment professionals led by CEO Ying Huang and CFO Lori Macomber, who assumed their roles in April 2024 (per the firm's official communications). The parent company maintains approximately 2,000 employees, though the investment team is a fraction of that total. In April 2024, Ying Huang was promoted from interim CEO to permanent CEO alongside her existing CFO responsibilities — signaling a consolidation of leadership at the highest level (per firm press release, April 2024). The office does not maintain a separate brand or public-facing website distinct from the parent biotech's corporate domain. The structural distinction lies in the office's proximity to active clinical development. Unlike most family offices that manage wealth from a concluded liquidity event, Legend's investment arm operates alongside an ongoing commercial franchise, giving its team access to proprietary scientific insights and a real-time view of cell-therapy innovation cycles. This embedded position — inside a company that is simultaneously a drug developer and an LP — creates a sourcing advantage in oncology-adjacent venture deals that peer family offices cannot replicate.